The short version
- In a randomised trial of 100 healthy adults aged 50 to 85 with age-associated memory impairment, 500mg of citicoline daily for twelve weeks improved episodic memory and a composite memory score, both reported as secondary outcomes.
- A 28-day randomised trial in 75 healthy adolescent males found improved attention (P = 0.02) and psychomotor speed (P = 0.03) on 250 or 500mg of citicoline, with a higher weight-adjusted dose predicting better accuracy and lower impulsivity.
- The Cochrane review of CDP-choline pooled 14 placebo-controlled trials and found no evidence of a beneficial effect on attention, but evidence of benefit on memory and behaviour.
- The ICTUS trial randomised 2,298 acute ischaemic stroke patients to citicoline or placebo, was stopped for futility, and found identical 90-day recovery (odds ratio 1.03, 95% CI 0.86 to 1.25).
- Most of the positive citicoline cognition trials were co-authored by employees of the company that manufactures the branded ingredient used in them.
Most ingredients in the focus aisle are supported by one small trial and a lot of enthusiasm. Citicoline is not one of those. It has a Cochrane review, a modern randomised trial in a hundred people, a trial in adolescents, and — unusually for a supplement — a 2,298-patient hospital trial that failed. Having a real failure in the file is a sign of a real evidence base.
So this article is not about whether the studies exist. It is about reading them properly, because the details change the size of the claim considerably.
The 2021 trial, and the word "secondary"
One hundred healthy men and women aged 50 to 85 with age-associated memory impairment were randomised to 500mg a day of citicoline or placebo for twelve weeks. Ninety-nine finished. Memory was tested on a computerised battery at baseline and at the end.
Two results were significant, and the paper labels both of them secondary outcomes: episodic memory on a paired-associate test (mean 0.15 versus 0.06, P = 0.0025) and a composite memory score built from four tests (mean 3.78 versus 0.72, P = 0.0052).
That distinction matters more than it sounds. A primary outcome is the question the trial was designed and powered to answer, declared in advance. Secondary outcomes are everything else it measured. A significant secondary outcome is a genuine finding and a weaker one, and honest reporting means saying which you have. This trial reported clearly. It is worth noticing that the abstract does not present a significant result on the primary.
The other thing worth noticing: three of the five authors work for Kyowa Hakko, the company that makes the branded citicoline used in the study.
The adolescent trial
Seventy-five healthy adolescent males were randomised to citicoline at 250 or 500mg (51 boys) or placebo (24 boys) for 28 days, then tested on selective attention, finger tapping and a computerised performance test. Attention improved (P = 0.02) and psychomotor speed improved (P = 0.03). A higher weight-adjusted dose predicted better accuracy on the attention task, better signal detectability, and lower impulsivity.
It is a clean positive, in a population almost nobody studies, with a dose-response relationship inside it — which is the kind of internal consistency that makes a result more believable. It is also 24 people in the placebo arm, four weeks long, and again co-authored by employees of the manufacturer.
What Cochrane found, and what it did not
The Cochrane review of CDP-choline — the same molecule, under its other name — pooled fourteen randomised, double-blind, placebo-controlled studies in older people with cognitive and behavioural disturbance from chronic cerebral disorders. Most ran 20 to 30 days; a few ran two to three months; one ran a year. Doses, delivery and inclusion criteria varied enormously.
The reviewers reported no evidence of a beneficial effect on attention, evidence of benefit on memory function and behaviour, and good tolerability. That split is the most useful sentence in the citicoline literature, because "focus" products are sold on attention and this is the one place a neutral body assessed it.
The trial that failed, and why we are showing it to you
In 2012 The Lancet published ICTUS: 2,298 patients with moderate-to-severe acute ischaemic stroke across 59 hospitals in Spain, Portugal and Germany, randomised to citicoline or placebo starting within 24 hours and continuing for six weeks. It was stopped for futility at the third interim analysis. Global recovery at 90 days was the same in both arms, odds ratio 1.03 (95% CI 0.86 to 1.25, P = 0.364).
Stroke is a different question from memory in a healthy 60-year-old, and a null there does not disprove the memory findings. But it does tell you something about the mechanism story. The reason citicoline was tried in stroke at all is the same membrane-phospholipid argument used to sell it for focus. In the largest, hardest test that argument ever faced, it did not produce an outcome.
So what should you take from this?
Citicoline is one of the better-evidenced things in this aisle, which is a statement about the aisle. Concretely: the human signal is on memory rather than attention, at 500mg a day, over four to twelve weeks, in older adults with age-related memory complaints and in one trial of adolescent boys. It is well tolerated everywhere it has been tested. Most of the positive work was run by the manufacturer, and the biggest independent test of the underlying mechanism failed.
Compare that with its neighbours and it holds up reasonably. bacopa monnieri asks for a twelve-week clock before it shows you anything and then delivers millisecond-scale changes. The caffeine and l-theanine combination is measured in the first two hours and gone by evening. Citicoline sits between them: weeks, not hours, and memory, not alertness.
What we'd actually tell you
If you are going to try it, use 500mg a day, which is the dose in the trial that most resembles the person likely to be reading this, and give it twelve weeks. Judge it on remembering — a name, a list, where you put the thing — and not on how alert you feel, because alertness is the one outcome Cochrane specifically did not find.
And keep the sponsorship in view. It does not make the results false. It makes them results that badly need someone with no stake to repeat them, and until that happens the correct expectation is modest.
Good questions
Does citicoline improve focus or memory?
Memory has the better evidence. The Cochrane review of 14 placebo-controlled trials found benefit on memory and behaviour but no evidence of an effect on attention, and the modern trials that worked measured episodic and composite memory. If you are buying it to concentrate for longer, you are buying it for the outcome with the weakest support.
How much citicoline should I take?
The trial most relevant to an adult buying this used 500mg a day for twelve weeks. An adolescent trial used 250 or 500mg for 28 days and found the higher weight-adjusted dose worked better. There is no good evidence that going above 500mg daily adds anything for a healthy adult.
Is citicoline the same thing as CDP-choline?
Yes. CDP-choline is the name used when the compound is discussed as a drug or as the molecule the body makes itself, and citicoline is the name used for the supplement and pharmaceutical product. Cochrane indexes the literature under CDP-choline, which is why searches for one name miss half the studies.
Should I trust studies funded by the company that sells the ingredient?
Not blindly, and not dismissively either. Industry-run trials can be well designed, and several of these are. What sponsorship changes is how much independent replication you should want before believing the size of the effect. For citicoline that replication has not happened, so the honest expectation is modest.
Why did citicoline fail in the stroke trial if it protects the brain?
Because a plausible mechanism is not a result. ICTUS gave 2,298 stroke patients citicoline within 24 hours and stopped early for futility, with recovery identical to placebo. That is the same membrane-phospholipid mechanism used to sell it for focus, tested at scale, producing nothing. It is a reason to keep expectations small.
Does citicoline have side effects?
Nothing consistent has been reported. The Cochrane review described the drug as well tolerated across its 14 trials, the 100-person memory trial monitored blood pressure, weight, haematology and metabolic panels without a signal, and the stroke trial found no difference in adverse events. The safety record is one of the better parts of this file.
Sources
- Nakazaki E, Mah E, Sanoshy K, Citrolo D, Watanabe F. Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Nutr, 2021. View study
- McGlade E, Agoston AM, DiMuzio J, et al. The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males. J Atten Disord, 2019. View study
- Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev, 2005. View study
- Dávalos A, Alvarez-Sabín J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet, 2012. View study
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
